<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01595737</url>
  </required_header>
  <id_info>
    <org_study_id>ACA-SPAI-2008-20</org_study_id>
    <nct_id>NCT01595737</nct_id>
  </id_info>
  <brief_title>Comparison of the Administration of Levosimendan and Placebo in the Preparation of Critical Patients for Heart Surgery</brief_title>
  <official_title>Comparison of the Administration of Levosimendan and Placebo in the Preparation of Critical Patients for Heart Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to examine the efficacy of levosimendan in terms of reducing postoperative
      mortality and severe morbidity in patients undergoing non-emergent surgery for coronary
      revascularisation with or without ischaemic mitral regurgitation and who may or may not
      require repair or replacement of the mitral valve and have a LVEF &lt; 35%.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Morbidity</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of morbidity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose of inotropic drugs used</measure>
    <time_frame>30 days</time_frame>
    <description>Requirements for inotropic drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of vasoactive drugs used</measure>
    <time_frame>30 days</time_frame>
    <description>Requirements for vasoactive drugs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Levosimendan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan</intervention_name>
    <description>Levosimendan perfusion for 12 hours before surgery by a single route, at a dosage of 0.1µg/kg/min without receiving the loading dose.</description>
    <arm_group_label>Levosimendan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo group patients will receive a perfusion of 5% glucose solution. This clear solution, free of visible particles, will have 0.4mg of riboflavin sodium phosphate, 100mg of anhydrous alcohol and water for injection up to 1ml added to it. This solution will be calculated as a dose of 0.1µg/kg/min.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female &gt; 18 years and &lt; 85 years.

          -  LVEF ≤ 35%

          -  Indication for elective surgery for coronary revascularisation, with or without mitral
             valve repair.

          -  Freely choose to participate in trial and sign an informed consent

        Exclusion Criteria:

          -  The patient does not accept the protocol.

          -  Allergy (hypersensitivity) to levosimendan, any of its components or to riboflavin.

          -  Severe hypotension or severe tachycardia prior to entering study.

          -  Significant mechanical obstruction affecting ventricular filling and/or emptying.

          -  History of Torsades.

          -  Requirement for inotropic or vasoactive drugs or any type of mechanical assistance for
             48 hours prior to surgery.

          -  Onset of angina or acute myocardial infarction within 48 hours prior to surgery, or
             cardiogenic shock.

          -  Surgery needs that are different from those planned.

          -  Chronic or severe kidney failure requiring haemodialysis or peritoneal dialysis or
             creatinine clearance values below 30ml/min or presence of nephrotic syndrome.

          -  Liver failure with transaminases 4 times above the normal maximum value.

          -  The patient must undergo a concurrently scheduled surgery, such as for a valve other
             than the mitral.

          -  When a screening cannot be performed at least during the 24 hours before surgery.

          -  Uncontrolled diabetes mellitus (blood glucose &gt; 24mmol/l or 432mg/dl).

          -  History of any disease over the last five years that may compromise the patient's
             life, other than their heart disease.

          -  The patient is currently abusing alcohol or toxic substances.

          -  Presence of any other medical or psychiatric condition that the researcher believes
             makes a candidate ineligible for the study.

          -  Women with childbearing potential who are not using an effective contraception method.

          -  Participation in the last 30 days in any other study with either experimental drugs or
             devices.

          -  Body Mass Index (BMI) greater than 35.

          -  Administration of levosimendan in the last 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2012</study_first_submitted>
  <study_first_submitted_qc>May 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2012</study_first_posted>
  <last_update_submitted>March 11, 2015</last_update_submitted>
  <last_update_submitted_qc>March 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

